Evidence map›Paper›PMID 27341789›Full record

ArticleSynapse (New York, N.Y.)2016

Estimating the effect of endogenous dopamine on baseline [(11) C]-(+)-PHNO binding in the human brain.

Fernando Caravaggio, Lawrence S Kegeles, Alan A Wilson, Gary Remington, Carol Borlido, David C Mamo, Ariel Graff-Guerrero

Open access · greenAbstract read
In one paragraph

Article in Synapse (New York, N.Y.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Preclinical Evaluation of the First Adenosine AJournal of medicinal chemistry · 2018
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Fernando CaravaggioCentre for Addiction and Mental Health, Research Imaging Centre, Toronto, Ontario, M5T 1R8, Canada.
Lawrence S KegelesDepartment of Psychiatry and Radiology, Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York.
Alan A WilsonCentre for Addiction and Mental Health, Research Imaging Centre, Toronto, Ontario, M5T 1R8, Canada.
Gary RemingtonCentre for Addiction and Mental Health, Research Imaging Centre, Toronto, Ontario, M5T 1R8, Canada.
Carol BorlidoCentre for Addiction and Mental Health, Research Imaging Centre, Toronto, Ontario, M5T 1R8, Canada.
David C MamoDepartment of Psychiatry, Faculties of Medicine and Health Science, University of Malta, Msida, Malta.
Ariel Graff-GuerreroCentre for Addiction and Mental Health, Research Imaging Centre, Toronto, Ontario, M5T 1R8, Canada. ariel.graff@camh.ca.
Centre for Addiction and Mental Health · CAUniversity of Toronto · CANew York State Psychiatric InstituteUniversity of Malta · MT

Funding

CIHR 114989-1
6 · The paper itself

Abstract

Endogenous dopamine (DA) levels at dopamine D2/3 receptors (D2/3 R) have been quantified in the living human brain using the agonist radiotracer [(11) C]-(+)-PHNO. As an agonist radiotracer, [(11) C]-(+)-PHNO is more sensitive to endogenous DA levels than antagonist radiotracers. We sought to determine the proportion of the variance in baseline [(11) C]-(+)-PHNO binding to D2/3 Rs which can be accounted for by variation in endogenous DA levels. This was done by computing the Pearson's coefficient for the correlation between baseline binding potential (BPND ) and the change in BPND after acute DA depletion, using previously published data. All correlations were inverse, and the proportion of the variance in baseline [(11) C]-(+)-PHNO BPND that can be accounted for by variation in endogenous DA levels across the striatal subregions ranged from 42-59%. These results indicate that lower baseline values of [(11) C]-(+)-PHNO BPND reflect greater stimulation by endogenous DA. To further validate this interpretation, we sought to examine whether these data could be used to estimate the dissociation constant (Kd) of DA at D2/3 R. In line with previous in vitro work, we estimated the in vivo Kd of DA to be around 20 nM. In summary, the agonist radiotracer [(11) C]-(+)-PHNO can detect the impact of endogenous DA levels at D2/3 R in the living human brain from a single baseline scan, and may be more sensitive to this impact than other commonly employed radiotracers.

Indexed as

AdultBrainDopamineDopamine AgonistsFemaleHumansMaleOxazinesPositron-Emission TomographyProtein BindingRadiopharmaceuticalsReceptors, Dopamine D2Receptors, Dopamine D3DopamineDopamine AgonistsnaxagolideOxazinesRadiopharmaceuticalsReceptors, Dopamine D2Receptors, Dopamine D3[11C]-(+)-PHNOAMPTD2/3RdopaminePET

Identifiers

PMID27341789
PMCPMC5328677
OpenAlexW2473895351

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.